Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17365
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBusuttil, Rita A-
dc.contributor.authorLiu, David Shi Hao-
dc.contributor.authorDi Costanzo, Natasha-
dc.contributor.authorSchröder, Jan-
dc.contributor.authorMitchell, Catherine-
dc.contributor.authorBoussioutas, Alex-
dc.date2018-
dc.date.accessioned2018-04-05T00:23:55Z-
dc.date.available2018-04-05T00:23:55Z-
dc.date.issued2018-01-16-
dc.identifier.citationScientific Reports 2018; 8(1): 825-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17365-
dc.description.abstractGastric cancer is a leading cause of cancer death worldwide, with advanced stage being correlated to the level of tumour invasion and metastasis. Current research is heavily focused on the identification and development of efficacious therapeutics targeting these fundamental hallmarks of cancer, however there are currently no animal models that mimic the invasive phenotypes observed in humans. To address this we have developed an orthotopic mouse model whereby gastric cancer cell lines are tagged with luciferase and injected into the subserosal layer of the stomach. This allows for the monitoring of primary tumour growth and metastasis in real-time as well as quantitation of the degree of tumour invasion through the stomach wall by immunohistochemistry. We have three models based on the degree of invasion and metastasis that are cell line specific: The AGS cells develop into invasive tumours by 4-weeks with no evidence of metastases, MKN45 cells are moderately metastatic with minimal invasion till week 2 and MKN28 cells are highly metastatic and fully invasive by week 1. These models have utility as a tool for testing the efficacy of anti-tumour, anti-invasive and anti-metastatic therapies in the setting of gastric cancer, which currently has poor treatment options.-
dc.language.isoeng-
dc.titleAn orthotopic mouse model of gastric cancer invasion and metastasis.-
dc.typeJournal Article-
dc.identifier.journaltitleScientific Reports-
dc.identifier.affiliationUpper Gastrointestinal Translational Research Laboratory, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia ..-
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationCancer Biology and Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Surgery, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationBioinformatics Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia-
dc.identifier.affiliationSchool of Computing and Information Systems, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Pathology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia-
dc.identifier.doi10.1038/s41598-017-19025-y-
dc.identifier.orcid0000-0001-8936-4123-
dc.identifier.pubmedid29339747-
dc.type.austinJournal Article-
local.name.researcherLiu, David Shi Hao
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptSurgery-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.